AtaiBeckley is a clinical-stage biopharmaceutical company that develops psychedelic-derived mental health treatments, created through the merger of atai Life Sciences and Beckley Psytech into a single entity with integrated psychedelic intellectual property and programs. The company focuses primarily on BPL-003, a 5-MeO-DMT-based intranasal compound for treatment-resistant depression, and is advancing MDMA-based therapies for social anxiety disorder through mid-stage clinical trials rather than operating as a venture capital fund.
Investors AT THE FUND
No items found.
Notable Investments
What Makes them Unique
Press & Media
No items found.
Sheets They're In
No items found.
Is this information out of date? Let us know
Popular fUNDS
Fund name
Active in
Rounds
Avg. Check
Links
.svg)
Or automatically find your investor matches
Upload your pitch deck to get your best investor matches in minutes.
Reveal the very best VCs to pitch for your startup
Get matching investors' email addresses
No ads. No catch. Free from VC Sheet.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Success. Check your email in 5 minutes.
.jpeg){kind=logo}
.png)
.jpeg)
.jpeg)
.jpeg)
